tirzepatide adolescent reduces HbA1c, BMI for children and adolescents with type 2 diabetes A Study to Evaluate Tirzepatide

Liu X, Wang Y, Zhang J, et al

In the original add-on epilepsy controlled trials (using rapid titration such as 100 to 200 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse events was 42% for 200 mg/day, 41% for 400 mg/day, 52% for 600 mg/day, 56% for 800 and 1000 mg/day, and 14% for placebo

The asymmetry between the three is, in many ways, the reason the literature on glutathione precursors exists at all

Changes in olive oil consumption and long-term body weight changes in U.S

Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner

Front Pharmacology